South Korea
· Delayed Price · Currency is KRW TiumBio Statistics
Total Valuation
TiumBio has a market cap or net worth of KRW 128.18 billion. The enterprise value is 144.80 billion.
| Market Cap | 128.18B |
| Enterprise Value | 144.80B |
Important Dates
The last earnings date was Thursday, November 14, 2024.
| Earnings Date | Nov 14, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
TiumBio has 26.03 million shares outstanding. The number of shares has increased by 3.90% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 26.03M |
| Shares Change (YoY) | +3.90% |
| Shares Change (QoQ) | +1.69% |
| Owned by Insiders (%) | 33.09% |
| Owned by Institutions (%) | 0.34% |
| Float | 12.27M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 15.62 |
| PB Ratio | 2.58 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -9.09 |
| EV / Sales | 18.31 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -4.15 |
Financial Position
The company has a current ratio of 2.57, with a Debt / Equity ratio of 0.44.
| Current Ratio | 2.57 |
| Quick Ratio | 2.25 |
| Debt / Equity | 0.44 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.78 |
| Interest Coverage | -5.04 |
Financial Efficiency
Return on equity (ROE) is -34.47% and return on invested capital (ROIC) is -15.14%.
| Return on Equity (ROE) | -34.47% |
| Return on Assets (ROA) | -12.85% |
| Return on Capital (ROIC) | -15.14% |
| Revenue Per Employee | 158.19M |
| Profits Per Employee | -318.72M |
| Employee Count | 50 |
| Asset Turnover | 0.08 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -25.49% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -25.49% |
| 50-Day Moving Average | 5,940.40 |
| 200-Day Moving Average | 6,781.15 |
| Relative Strength Index (RSI) | 35.10 |
| Average Volume (20 Days) | 122,454 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, TiumBio had revenue of KRW 7.91 billion and -15.94 billion in losses. Loss per share was -635.40.
| Revenue | 7.91B |
| Gross Profit | 7.91B |
| Operating Income | -19.96B |
| Pretax Income | -17.66B |
| Net Income | -15.94B |
| EBITDA | -16.53B |
| EBIT | -19.96B |
| Loss Per Share | -635.40 |
Balance Sheet
The company has 22.63 billion in cash and 27.24 billion in debt, giving a net cash position of -4.61 billion or -177.17 per share.
| Cash & Cash Equivalents | 22.63B |
| Total Debt | 27.24B |
| Net Cash | -4.61B |
| Net Cash Per Share | -177.17 |
| Equity (Book Value) | 61.68B |
| Book Value Per Share | 1,908.26 |
| Working Capital | 17.24B |
Cash Flow
In the last 12 months, operating cash flow was -19.04 billion and capital expenditures -15.82 billion, giving a free cash flow of -34.86 billion.
| Operating Cash Flow | -19.04B |
| Capital Expenditures | -15.82B |
| Free Cash Flow | -34.86B |
| FCF Per Share | -1,339.45 |
Margins
Gross margin is 100.00%, with operating and profit margins of -252.30% and -201.48%.
| Gross Margin | 100.00% |
| Operating Margin | -252.30% |
| Pretax Margin | -223.30% |
| Profit Margin | -201.48% |
| EBITDA Margin | -209.00% |
| EBIT Margin | -252.30% |
| FCF Margin | -440.73% |
Dividends & Yields
TiumBio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3.90% |
| Shareholder Yield | -3.90% |
| Earnings Yield | -12.90% |
| FCF Yield | -27.20% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
TiumBio has an Altman Z-Score of 0.61. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.61 |
| Piotroski F-Score | n/a |